Personalis CEO Christopher Hall Sells 100,000 Shares Amid Stock Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 55 minutes ago
0mins
Source: NASDAQ.COM
- Insider Selling: Personalis CEO Christopher Hall sold 100,000 shares of common stock between May 28 and May 29, 2026, for approximately $1.10 million at an average price of $11.02 per share, indicating executive confidence and sensitivity to market dynamics.
- Transaction Context: This sale was a derivative transaction involving option exercise, with Hall not holding shares indirectly prior to the sale, suggesting he retains substantial control over future equity acquisitions, potentially allowing for further stock purchases.
- Market Reaction: Concurrently, Personalis shares reached a 52-week high of $11.85 on May 29, reflecting strong performance in the cancer genomics sector and optimistic market sentiment regarding the company's growth prospects.
- Financial Outlook: The company forecasts 2026 revenue between $78 million and $80 million, up from $69.6 million last year, driving the price-to-sales ratio to 16, indicating high valuation; Hall's timely sale is viewed as a strategic decision, prompting investors to monitor market trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.780
Low
10.00
Averages
11.17
High
12.00
Current: 10.780
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeXT Personal® MRD Test Shows 100% Sensitivity for CRC Recurrence
- Colorectal Cancer Monitoring: The VICTORI study demonstrated that NeXT Personal detected 100% of relapses in colorectal cancer patients, surpassing imaging methods, highlighting its critical role in early intervention and potentially transforming clinical management strategies.
- Early Post-Surgery Signals: The test identified 82% of relapses within four weeks post-surgery, providing clinicians with a reliable early signal that optimizes treatment pathways and enhances patient survival rates.
- Ultra-Sensitive Lung Cancer Detection: The TRACERx study revealed that NeXT Personal achieved a median limit of detection of 1.66 ppm in 431 non-small cell lung cancer patients, with approximately 21% of pre-operative adenocarcinoma detections below 10 ppm, underscoring its potential for early intervention.
- Broad Application Across Tumor Types: NeXT Personal exhibited exceptional performance in ovarian, endometrial, and melanoma cancers, suggesting its potential as a non-invasive alternative detection method, which could drive a new paradigm in cancer management.
See More
Personalis CEO Sells 100,000 Shares Amid Stock Surge
- Executive Sale Transaction: Christopher M. Hall, CEO of Personalis, directly sold 100,000 shares of common stock on May 29, 2026, valued at approximately $1.1 million, indicating his continued confidence in the company despite a 29.76% reduction in direct holdings.
- Ownership Analysis: Post-transaction, Hall retains 235,986 shares of common stock, representing a remaining direct equity position valued at around $2.6 million, suggesting optimism about the company's future and the capacity to increase holdings through 300,000 outstanding options.
- Transaction Context: This sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025, aimed at avoiding insider trading allegations, indicating that Hall's sale was planned rather than a reaction to market conditions, alleviating investor concerns.
- Market Reaction and Outlook: During Hall's sale, Personalis shares surged due to expanded Medicare coverage for its NeXT Personal product and an upward revision of 2026 revenue forecasts to between $78 million and $80 million, highlighting the company's robust growth potential in the precision medicine sector.
See More
Personalis CEO Christopher Hall Sells 100,000 Shares Amid Stock Surge
- Insider Selling: Personalis CEO Christopher Hall sold 100,000 shares of common stock between May 28 and May 29, 2026, for approximately $1.10 million at an average price of $11.02 per share, indicating executive confidence and sensitivity to market dynamics.
- Transaction Context: This sale was a derivative transaction involving option exercise, with Hall not holding shares indirectly prior to the sale, suggesting he retains substantial control over future equity acquisitions, potentially allowing for further stock purchases.
- Market Reaction: Concurrently, Personalis shares reached a 52-week high of $11.85 on May 29, reflecting strong performance in the cancer genomics sector and optimistic market sentiment regarding the company's growth prospects.
- Financial Outlook: The company forecasts 2026 revenue between $78 million and $80 million, up from $69.6 million last year, driving the price-to-sales ratio to 16, indicating high valuation; Hall's timely sale is viewed as a strategic decision, prompting investors to monitor market trends.
See More
SPDR S&P Oil & Gas ETF Underperforms
- ETF Performance: The SPDR S&P Oil & Gas Equipment & Services ETF is down approximately 1.8% in Thursday afternoon trading, indicating market concerns about the sector that could impact investor confidence.
- Weak Individual Stocks: Within the ETF, Atlas Energy Solutions shares fell about 6%, while Flowco Holdings dropped approximately 4.7%, reflecting poor market performance for these companies that may lead investors to reassess their portfolios.
- Market Sentiment Impact: The overall weak performance of the oil and gas sector may cause investors to adopt a cautious stance towards related stocks, potentially affecting capital inflows into the industry.
- Uncertain Industry Outlook: Given the current economic environment, the oil and gas equipment and services sector faces challenges that could suppress the ETF's long-term performance, prompting investors to monitor industry developments for informed decision-making.
See More
Personalis Secures Expanded Medicare Coverage for NeXT Personal Test
- Medicare Decision Impact: Personalis (PSNL) shares rose approximately 5% in premarket trading on Wednesday after the company received its fourth Medicare decision, which broadens coverage for its NeXT Personal minimal residual disease test in the U.S., likely boosting market demand significantly.
- Clinical Application Expansion: The latest determination by the U.S. Centers for Medicare & Medicaid Services will expand NeXT Personal's clinical use to include stage II and III triple-negative breast cancer or HER2-positive breast cancer patients, enhancing its competitive edge in cancer monitoring.
- Reimbursement Policy Change: This decision allows Medicare beneficiaries to receive reimbursement for NeXT Personal's use in monitoring treatment response to neoadjuvant therapy, marking a coverage expansion following Medicare's previous determination for recurrence monitoring after surgery, further solidifying its market position.
- Future Performance Outlook: Personalis targets a clinical volume of 43,000 to 45,000 tests for 2026 while reaffirming its revenue guidance of $78 million to $80 million, demonstrating the company's confidence in future growth.
See More
Medicare Expands MRD Testing Coverage for TNBC and HER2+ Cancer Patients
- Coverage Expansion: The Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for Personalis' NeXT Personal minimal residual disease (MRD) test, enabling monitoring of treatment response in Stage II-III Triple-Negative Breast Cancer (TNBC) and HER2-positive patients, marking the company's fourth Medicare coverage milestone in breast cancer.
- Clinical Evidence Support: This decision is backed by the PREDICT-DNA study published in the Journal of Clinical Oncology, which tracked 227 patients with TNBC and HER2+ breast cancer across 24 leading US cancer centers, demonstrating that NeXT Personal's ultrasensitive ctDNA monitoring outperforms traditional clinical metrics in predicting long-term patient outcomes.
- Significant Technical Advantage: The study revealed that nearly half of all ctDNA detections post-neoadjuvant therapy occurred at levels below 100 parts per million (PPM), while NeXT Personal can track up to approximately 1,800 patient-specific variants, providing the high resolution needed for physicians to accurately monitor treatment responses.
- Strategic Implications: Personalis CEO Chris Hall stated that this coverage expansion moves their technology into active treatment management, aiming to improve clinical outcomes for patients through their ultrasensitive MRD technology, further advancing the transformation of cancer care through personalized testing.
See More
NeXT Personal® MRD Test Shows 100% Sensitivity for CRC Recurrence
- Colorectal Cancer Monitoring: The VICTORI study demonstrated that NeXT Personal detected 100% of relapses in colorectal cancer patients, surpassing imaging methods, highlighting its critical role in early intervention and potentially transforming clinical management strategies.
- Early Post-Surgery Signals: The test identified 82% of relapses within four weeks post-surgery, providing clinicians with a reliable early signal that optimizes treatment pathways and enhances patient survival rates.
- Ultra-Sensitive Lung Cancer Detection: The TRACERx study revealed that NeXT Personal achieved a median limit of detection of 1.66 ppm in 431 non-small cell lung cancer patients, with approximately 21% of pre-operative adenocarcinoma detections below 10 ppm, underscoring its potential for early intervention.
- Broad Application Across Tumor Types: NeXT Personal exhibited exceptional performance in ovarian, endometrial, and melanoma cancers, suggesting its potential as a non-invasive alternative detection method, which could drive a new paradigm in cancer management.
See More
Personalis CEO Sells 100,000 Shares Amid Stock Surge
- Executive Sale Transaction: Christopher M. Hall, CEO of Personalis, directly sold 100,000 shares of common stock on May 29, 2026, valued at approximately $1.1 million, indicating his continued confidence in the company despite a 29.76% reduction in direct holdings.
- Ownership Analysis: Post-transaction, Hall retains 235,986 shares of common stock, representing a remaining direct equity position valued at around $2.6 million, suggesting optimism about the company's future and the capacity to increase holdings through 300,000 outstanding options.
- Transaction Context: This sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025, aimed at avoiding insider trading allegations, indicating that Hall's sale was planned rather than a reaction to market conditions, alleviating investor concerns.
- Market Reaction and Outlook: During Hall's sale, Personalis shares surged due to expanded Medicare coverage for its NeXT Personal product and an upward revision of 2026 revenue forecasts to between $78 million and $80 million, highlighting the company's robust growth potential in the precision medicine sector.
See More
Personalis CEO Christopher Hall Sells 100,000 Shares Amid Stock Surge
- Insider Selling: Personalis CEO Christopher Hall sold 100,000 shares of common stock between May 28 and May 29, 2026, for approximately $1.10 million at an average price of $11.02 per share, indicating executive confidence and sensitivity to market dynamics.
- Transaction Context: This sale was a derivative transaction involving option exercise, with Hall not holding shares indirectly prior to the sale, suggesting he retains substantial control over future equity acquisitions, potentially allowing for further stock purchases.
- Market Reaction: Concurrently, Personalis shares reached a 52-week high of $11.85 on May 29, reflecting strong performance in the cancer genomics sector and optimistic market sentiment regarding the company's growth prospects.
- Financial Outlook: The company forecasts 2026 revenue between $78 million and $80 million, up from $69.6 million last year, driving the price-to-sales ratio to 16, indicating high valuation; Hall's timely sale is viewed as a strategic decision, prompting investors to monitor market trends.
See More
SPDR S&P Oil & Gas ETF Underperforms
- ETF Performance: The SPDR S&P Oil & Gas Equipment & Services ETF is down approximately 1.8% in Thursday afternoon trading, indicating market concerns about the sector that could impact investor confidence.
- Weak Individual Stocks: Within the ETF, Atlas Energy Solutions shares fell about 6%, while Flowco Holdings dropped approximately 4.7%, reflecting poor market performance for these companies that may lead investors to reassess their portfolios.
- Market Sentiment Impact: The overall weak performance of the oil and gas sector may cause investors to adopt a cautious stance towards related stocks, potentially affecting capital inflows into the industry.
- Uncertain Industry Outlook: Given the current economic environment, the oil and gas equipment and services sector faces challenges that could suppress the ETF's long-term performance, prompting investors to monitor industry developments for informed decision-making.
See More
Personalis Secures Expanded Medicare Coverage for NeXT Personal Test
- Medicare Decision Impact: Personalis (PSNL) shares rose approximately 5% in premarket trading on Wednesday after the company received its fourth Medicare decision, which broadens coverage for its NeXT Personal minimal residual disease test in the U.S., likely boosting market demand significantly.
- Clinical Application Expansion: The latest determination by the U.S. Centers for Medicare & Medicaid Services will expand NeXT Personal's clinical use to include stage II and III triple-negative breast cancer or HER2-positive breast cancer patients, enhancing its competitive edge in cancer monitoring.
- Reimbursement Policy Change: This decision allows Medicare beneficiaries to receive reimbursement for NeXT Personal's use in monitoring treatment response to neoadjuvant therapy, marking a coverage expansion following Medicare's previous determination for recurrence monitoring after surgery, further solidifying its market position.
- Future Performance Outlook: Personalis targets a clinical volume of 43,000 to 45,000 tests for 2026 while reaffirming its revenue guidance of $78 million to $80 million, demonstrating the company's confidence in future growth.
See More
Medicare Expands MRD Testing Coverage for TNBC and HER2+ Cancer Patients
- Coverage Expansion: The Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for Personalis' NeXT Personal minimal residual disease (MRD) test, enabling monitoring of treatment response in Stage II-III Triple-Negative Breast Cancer (TNBC) and HER2-positive patients, marking the company's fourth Medicare coverage milestone in breast cancer.
- Clinical Evidence Support: This decision is backed by the PREDICT-DNA study published in the Journal of Clinical Oncology, which tracked 227 patients with TNBC and HER2+ breast cancer across 24 leading US cancer centers, demonstrating that NeXT Personal's ultrasensitive ctDNA monitoring outperforms traditional clinical metrics in predicting long-term patient outcomes.
- Significant Technical Advantage: The study revealed that nearly half of all ctDNA detections post-neoadjuvant therapy occurred at levels below 100 parts per million (PPM), while NeXT Personal can track up to approximately 1,800 patient-specific variants, providing the high resolution needed for physicians to accurately monitor treatment responses.
- Strategic Implications: Personalis CEO Chris Hall stated that this coverage expansion moves their technology into active treatment management, aiming to improve clinical outcomes for patients through their ultrasensitive MRD technology, further advancing the transformation of cancer care through personalized testing.
See More
